Vivecon is an investigational new drug in development for the treatment of HIV infection. It is a maturation inhibitor.

Mechanism of action

Vivecon targets the gag polyprotein precursor, the main structural protein responsible for assembly and budding of virion particles. By binding to the gag polyprotein, vivecon prevents its cleavage by the protease enzyme into functional subunits. Unlike the protease inhibitors, vivecon binds the gag protein, not the protease enzyme. The resulting virus particles are structurally defective and are incapable of spreading infection through the body.[1]


Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Entry/fusion inhibitors </br> (Discovery & development)
Integrase inhibitors
Maturation inhibitors
Protease Inhibitors (PI)</br>(Discovery and development)
1st generation
2nd generation
Combined formulations
Experimental agents
Failed agents

This article uses material from the Wikipedia article Vivecon, that was deleted or is being discussed for deletion, which is released under the Creative Commons Attribution-ShareAlike 3.0 Unported License.
Author(s): Anypodetos Search for "Vivecon" on Google
View Wikipedia's deletion log of "Vivecon"

Ad blocker interference detected!

Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.